Istituto Superiore di Sanità, Department of Infectious, Parasitic and Immunomediated Diseases, Rome, Italy.
Expert Rev Vaccines. 2010 Aug;9(8):913-24. doi: 10.1586/erv.10.84.
Human papillomaviruses are the etiological agents of cervical cancer, one of the two most prevalent cancers in women in developing countries. Currently available prophylactic vaccines are based on the L1 major capsid protein, which forms virus-like particles when expressed in yeast and insect cell lines. Despite their recognized efficacy, there are significant shortcomings: the vaccines are expensive, include only two oncogenic virus types, are delivered via intramuscular injection and require a cold chain. Plant expression systems may provide ways of overcoming some of these problems, in particular the expense. In this article, we report recent promising advances in the production of prophylactic and therapeutic vaccines against human papillomavirus by expression of the relevant antigens in plants, and discuss future prospects for the use of such vaccines.
人乳头瘤病毒是宫颈癌的病因之一,宫颈癌是发展中国家女性中最常见的两种癌症之一。目前可用的预防性疫苗基于 L1 主要衣壳蛋白,当在酵母和昆虫细胞系中表达时,它形成病毒样颗粒。尽管它们被认为是有效的,但仍存在显著的缺点:疫苗昂贵,仅包含两种致癌病毒类型,通过肌内注射给药,且需要冷链。植物表达系统可能提供克服其中一些问题的方法,特别是费用问题。在本文中,我们报告了在植物中表达相关抗原生产预防性和治疗性 HPV 疫苗方面的最新进展,并讨论了此类疫苗的未来前景。